Latest JOHNSON & JOHNSON Stock Portfolio

JOHNSON & JOHNSON Performance:

2025 Q2: -3.24%YTD: -2.45%2024: -4.19%

Performance for 2025 Q2 is -3.24%, and YTD is -2.45%, and 2024 is -4.19%.

About JOHNSON & JOHNSON and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, JOHNSON & JOHNSON reported an equity portfolio of $334.1 Millions as of 30 Jun, 2025.

The top stock holdings of JOHNSON & JOHNSON are PTGX, MGTX, . The fund has invested 40.8% of it's portfolio in PROTAGONIST THERAPEUTICS INC. and 13.1% of portfolio in MEIRAGTX HOLDINGS PLC.

They significantly reduced their stock positions in LYELL IMMUNOPHARMA INC. (LYEL).

JOHNSON & JOHNSON Annual Return Estimates Vs S&P 500

Our best estimate is that JOHNSON & JOHNSON made a return of -3.24% in the last quarter. In trailing 12 months, it's portfolio return was 3.74%.

New Buys

No new stocks were added by JOHNSON & JOHNSON

Additions

No additions were made to existing positions by JOHNSON & JOHNSON

Reductions

Ticker	% Reduced
lyell immunopharma inc.	0.00

JOHNSON & JOHNSON reduced stake in above stock

Sold off

None of the stocks were completely sold off by JOHNSON & JOHNSON

Sector Distribution

JOHNSON & JOHNSON has about 72.3% of it's holdings in Healthcare sector.

Sector	%
Healthcare	72.3
Others	27.7

Market Cap. Distribution

JOHNSON & JOHNSON has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	48.1
UNALLOCATED	27.7
SMALL-CAP	16.2
MICRO-CAP	7.9

Stocks belong to which Index?

About 72.4% of the stocks held by JOHNSON & JOHNSON either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	72.4
Others	27.6

Top 5 Winners (%)		%
VOR	vor biopharma, inc.	47.7 %
FATE	fate therapeutics, inc.	31.6 %
ARWR	arrowhead pharmaceuticals, inc.	26.2 %
PTGX	protagonist therapeutics inc.	15.2 %
LAB	standard biotools inc	10.2 %

Top 5 Winners ($)		$
PTGX	protagonist therapeutics inc.	18.0 M
FATE	fate therapeutics, inc.	0.8 M
ARWR	arrowhead pharmaceuticals, inc.	0.8 M
VOR	vor biopharma, inc.	0.4 M
LAB	standard biotools inc	0.0 M

Top 5 Losers (%)		%
CVRX	cvrx, inc.	-52.4 %
RLYB	rallybio corporation	-49.2 %
SENS	senseonics holdings, inc.	-24.7 %
XNCR	xencor, inc.	-23.5 %
PHGE	biomx inc.	-20.8 %

Top 5 Losers ($)		$
CVRX	cvrx, inc.	-26.3 M
XNCR	xencor, inc.	-1.9 M
RLYB	rallybio corporation	-1.2 M
MGTX	meiragtx holdings plc	-1.1 M
PRCT	procept biorobotics corporation	-0.5 M

JOHNSON & JOHNSON Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of JOHNSON & JOHNSON

JOHNSON & JOHNSON has 20 stocks in it's portfolio. About 97.3% of the portfolio is in top 10 stocks. CVRX proved to be the most loss making stock for the portfolio. PTGX was the most profitable stock for JOHNSON & JOHNSON last quarter.

Last Reported on: 22 Jul, 2025

	Ticker	Namesorted descending	% Portfolio	Shares Held	$ Value	Type	% Change
	PTGX	protagonist therapeutics inc.	40.83	2,449,180	136,395,000	unchanged	0.00
Historical Trend of PROTAGONIST THERAPEUTICS INC. Position Held By JOHNSON & JOHNSON What % of Portfolio is PTGX?: Number of PTGX shares held: Change in No. of Shares Held:
	MGTX	meiragtx holdings plc	13.14	6,641,060	43,897,400	unchanged	0.00

		rapport therapeutics, inc.	8.55	2,498,050	28,552,700	unchanged	0.00

		legend biotech corporation	8.44	814,586	28,209,100	unchanged	0.00

	NBTX	nanobiotix s.a.	7.62	5,623,820	25,454,500	unchanged	0.00

	CVRX	cvrx, inc.	7.15	4,103,430	23,882,000	unchanged	0.00

	PRCT	procept biorobotics corporation	6.10	357,939	20,370,300	unchanged	0.00

		contineum therapeutics inc.	2.44	1,979,170	8,134,400	unchanged	0.00

	XNCR	xencor, inc.	1.82	748,062	6,089,220	unchanged	0.00

	ARWR	arrowhead pharmaceuticals, inc.	1.19	247,598	3,981,380	unchanged	0.00

	FATE	fate therapeutics, inc.	1.05	3,379,060	3,514,230	unchanged	0.00

		neumora therapeutics, inc.	0.42	1,849,440	1,399,840	unchanged	0.00

	RLYB	rallybio corporation	0.36	3,636,360	1,209,450	unchanged	0.00

	VOR	vor biopharma, inc.	0.34	1,074,660	1,139,140	unchanged	0.00

	NNOX	nano-x imaging ltd.	0.25	158,852	830,796	unchanged	0.00

	LAB	standard biotools inc	0.11	311,967	371,241	unchanged	0.00

	LYEL	lyell immunopharma inc.	0.11	41,165	368,015	reduced	0.00

	ACET	adicet bio, inc.	0.07	364,472	228,014	unchanged	0.00

	PHGE	biomx inc.	0.01	96,866	42,621	unchanged	0.00

	SENS	senseonics holdings, inc.	0.01	54,621	26,988	unchanged	0.00